OVT-101

N/A

Report date: 2026/04/20 20:01:59

First In Class

Base Information

Drug NameOVT-101

Drug Alias NameOVT-101OVT101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionClaudin 6 modulators

TargetsClaudin 6

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOverT Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesOverT Bio Inc

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A